Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..
2016.
Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.
Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..
2016.
A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.
Page DB, Yuan J, Redmond D, Y Wen H, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C et al..
2016.
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.. Cancer Immunol Res. 4(10):835-844.
Allen JE, C Kline LB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A et al..
2016.
Discovery and clinical introduction of first-in-class imipridone ONC201.. Oncotarget. 7(45):74380-74392.
Béguelin W, Teater M, Gearhart MD, Fernández MTeresa Cal, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM et al..
2016.
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.. Cancer Cell. 30(2):197-213.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..
2016.
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.
Elemento O.
2016.
KLF4: A new player in plasma cell development.. Cell Cycle. 15(20):2691-2.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..
2016.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.
Takemoto A, Kawashima SA, Li J-J, Jeffery L, Yamatsugu K, Elemento O, Nurse P.
2016.
Nuclear envelope expansion is crucial for proper chromosomal segregation during a closed mitosis.. J Cell Sci. 129(6):1250-9.